免疫检查点抑制剂为主的联合疗法治疗经典型霍奇金淋巴瘤的研究现状  

Research status on immune checkpoint inhibitor-based combination therapy in classic Hodgkin lymphoma

作　　者：李开然 徐开林 朱锋 Li Kairan;Xu Kailin;Zhu Feng(First Clinical Medical College of Xuzhou Medical University,Xuzhou 221002,Jiangsu Province,China;Department of Hematology,Affiliated Hospital of Xuzhou Medical University,Xuzhou 221006,Jiangsu Province,China)

机构地区：[1]徐州医科大学第一临床学院,徐州221002 [2]徐州医科大学附属医院血液科,徐州221006

出　　处：《国际输血及血液学杂志》2022年第5期369-374,共6页International Journal of Blood Transfusion and Hematology

基　　金：国家自然科学基金(82170187);江苏省"六个一工程"拔尖人才科研项目(LGY2018084)。

摘　　要：经典型霍奇金淋巴瘤(cHL)被认为是一类可被治愈的疾病, 但是仍有少部分cHL患者难治或治疗后复发。近年来, 免疫检查点抑制剂(ICI)治疗成为继放化疗及靶向治疗后cHL治疗的新方向, 其中细胞毒性T淋巴细胞相关抗原(CTLA)-4和程序性死亡受体(PD)-1是目前主要的免疫检查点, ICI治疗cHL患者具有良好效果。笔者通过对以ICI为主的联合疗法在cHL患者的应用及免疫相关不良事件(irAR)的管理等研究现状进行阐述, 旨在为cHL患者的治疗提供新思路。Classical Hodgkin lymphoma(cHL)is currently considered as a curable disease,but there are still a small number of patients with cHL who are refractory or relapsed after treatment.In recent years,immune checkpoint inhibitors(ICI)is a new direction of cHL treatment after chemoradiotherapy and targeted therapy.Cytotoxic T-lymophocyte-associated antigen(CTLA)-4 and programmed cell death receptor(PD)-1 are the main immune checkpoints at present.These ICI have achieved good efficacy in cHL.This article aims to provide new ideas for treatment of patients with cHL by describing the current research status on use of ICI-based combination therapies in cHL patients and management of immune-related adverse events(irAR).

关 键 词：霍奇金病 免疫检查点抑制剂 T淋巴细胞 细胞毒性 程序性死亡受体1 药物疗法 联合 药物毒性 

分 类 号：R733.1[医药卫生—肿瘤]